Table 4

Developmental assessment in 7 patients younger than 2.5 years of age (patient nos. 1, 2, 3, 4, 6, 7, and 8)

Median (range) PA-CA difference at M0Median (range) PA-CA difference at M12Median (range) change M0 vs. M12*N improved ptsP**N of affected at M0/M12
Global development−2.5 (−3.5 to 1)−2.5 (−5 to 3)−0.5 (−4 to 3.5)00.665/5
Posture−2 (−3.5 to 1)−1 (−5 to 3.5)0.8 (−5 to 3.5)10.844/3
Coordination−2.5 (−4.5 to 1)−2.5 (−8 to 2.5)−0.5 (−4 to 3.5)10.814/4
Language−2.5 (−5.5 to 1)−4.5 (−5 to 3.5)−1.3 (−5 to 4.5)00.384/5
Sociability−2 (−5.5 to 0.5)−2.5 (−5 to 1.5)−1 (−2.5 to 2.5)00.474/4
  • Patients were tested using the Brunet-Lézine test at baseline and then 12 months after starting SU therapy.

  • CA, chronological age; M0, baseline (just before starting SU therapy); M12, 12 months after starting SU therapy; PA, performance age; pts, patients.

  • *One patient (patient 2) was not evaluated at the 12-month time point.

  • **Paired Wilcoxon test on continuous scores.